Term
| Based on genomic structure, RNA + must be switched to RNA - before becoming mRNA |
|
Definition
| Baltimore classification of viruses |
|
|
Term
|
Definition
|
|
Term
|
Definition
| if left untreated die within 48 hours |
|
|
Term
|
Definition
| rare in general population, common in immunocompromised |
|
|
Term
|
Definition
|
|
Term
| Gastroenteritis: bacterial |
|
Definition
| much more serious, not self limiting |
|
|
Term
|
Definition
|
|
Term
| Pneumonia: bacterial and fungal |
|
Definition
|
|
Term
| Three major categories of chemotherapy of viral infections |
|
Definition
| Virucidal, antiviral, immunomodulating |
|
|
Term
|
Definition
| smallpox, polio, #1 means of control |
|
|
Term
|
Definition
|
|
Term
| usually too toxic, directly kill viruses in their free form (ex: gluteraldehyde, used to disinfect things) |
|
Definition
|
|
Term
| inhibits viral replication, reversible (nothing says it is killing the virus, like a bacteriostatic agent) |
|
Definition
|
|
Term
| alters host response (interferon's, anti-nodes, don't act on viruses directly but alters host response |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| > 40% (Hepadnavirus, dsDNA) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| mononucleosis, burkitt's lymphoma, nasopharyngeal carcinoma |
|
Definition
|
|
Term
|
Definition
|
|
Term
| all renally excreted unchanged; prodrugs that are step-wise activated by kinases |
|
Definition
|
|
Term
|
Definition
| generally teratogenic and mutagenic in vitro |
|
|
Term
|
Definition
|
|
Term
| has deeoxyribose, H on sugar |
|
Definition
|
|
Term
|
Definition
| Primary and recurrent genital herpes,herpetic keratitis; generally more effective in primary than recurrent episodes |
|
|
Term
|
Definition
| suppression of recurrent genital herpes and mucocutaneous infections in immunocompromised hosts; varicella zoster w/in 72 hours; varicella w/in 24 hours |
|
|
Term
|
Definition
| HSV encephalitis; rapid infusion causes crystalline nephropathy |
|
|
Term
| Gangliciclovir used orally |
|
Definition
| Poor (<5%) oral bioavailability |
|
|
Term
|
Definition
| serious CMV infections in immunocompromised host; retinitis, esophagitis, colitis, cholangitis, pneumonia; prophylactic use emerging |
|
|
Term
| Gangliciclovir severe toxicity |
|
Definition
| anemia, neutropenia, thrombocytopenia (<40%) |
|
|
Term
| Gangliciclovir CNS toxicity |
|
Definition
| headache, psychosis, convulsions(not limited to nucleoside analogues) |
|
|
Term
| Major use in LRTI due to respiratory syncytial virus (RSV) in pediatric with underlying disease |
|
Definition
|
|
Term
| Active against most HSV and CMV; administered IV |
|
Definition
|
|
Term
| Foscarnet adverse effects |
|
Definition
| renal insufficiency, malaise, N/V; tremor, seizures, irritability, hallucinations |
|
|
Term
| Also used in Parkinson's disease: increases nigrostriatal DAergic output |
|
Definition
|
|
Term
| Amantadine Treatment and chemoprophylaxis |
|
Definition
| influenza A only; compatibile with influenza vaccine |
|
|
Term
|
Definition
| dry mouth, constipation, urinary constriction (AntiACh releated effects) |
|
|
Term
| Reduces severity and duration of influenza symptoms; well tolerated; first influenza-specific family of drugs |
|
Definition
| oseltamivir and zanamivir |
|
|
